0:00
Hello.
This is Daniel Swerdlow
and Michael Holmes.
And welcome to this talk
about some of the challenges
faced in developing new
drugs for the treatment
and prevention of
cardiovascular disease.
0:15
This talk will concentrate
on pharmacological therapy
for the principal areas of
cardiovascular disease--
coronary heart disease
including myocardial infarction
and related conditions, stroke
and other cerebrovascular
disease, and peripheral
vascular disease.
As the global burden of
cardiovascular disease
continues to grow and novel
therapeutic strategies are
relatively scarce, we will
address five key challenges faced
in finding new
approaches to treating
and preventing
cardiovascular disease.
First, the identification of new
therapeutic targets beyond those
modulated by conventional therapy.
Second, we will examine methods
for validating potential targets
early in drug development process.
Safety of new medicines
is increasingly important
and is subject to growing
external regulation.
We consider techniques for
predicting and evaluating
adverse drug effect in order to
prevent and reduce patient harm.
Fourth, we discuss the use of
pharmacogenetics, an expanding
approach that uses
a patient's genotype
to optimize their
pharmacological therapy.
And finally, we propose a strategy
for integrating new techniques
into the drug development pipeline
in order to expedite the transfer
of safe, effective new therapies
into clinical practice.
1:28
Our first challenge is the
identification of new targets
for treating and preventing
cardiovascular disease.
1:40
There is currently a large range
of pharmaceutical agents used
for the prevention and treatment
of cardiovascular disease.
There are, however,
a relatively limited
number of therapeutic targets.
Conventional therapy aims to
reduce cholesterol, blood pressure,
and to some extent
inflammation and to inhibit
coagulation and thrombosis.
It is likely, however, that many
more targets and pathological
mechanisms lie undiscovered that
could be valuable novel targets for
the cardiovascular
disease prevention.
And it is the identification
of those targets that
is the first challenge
we will examine.
